logo
portrait of smiling man stading in wooded areaportrait of smiling man stading in wooded areablue triangle graphic


Great Science
Deep Compassion
Real Impact

Working together to address addiction,
serious mental illness and cancer.

Discover Alkermes

Featured News

March 15, 2023

Alkermes to Participate in the Stifel 2023 CNS Days

Read more

February 16, 2023

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

Read more

January 17, 2023

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.

Pride@Work

Our company possesses a profound power to help shape a more inclusive and equitable society for all. We recognize the importance of our role. See what our valued co-leaders have to say about their involvement with Pride@Work, our employee resource group for LGBTQ+ employees and allies.

Meet the co-leaders

Driven by Passion

Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.

Learn more about our culture

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

Inspiring Programs

Now in its sixth year, we are proud of the impact the Alkermes Inspiration Grants® program has made in support of creative and innovative programs designed to make a difference for patient communities. Our most recent grant recipients were announced in October 2022.

Visit the program page

Pipeline Preview


We seek to develop treatments that address unmet patient needs in complex and difficult-to-treat diseases in the areas of neuroscience and oncology. Our pipeline is comprised of clinical and preclinical candidates generated from our scientific platforms, including synaptic dysfunction in neuroscience and immune modulation in oncology.

View our pipeline

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

  • Neuroscience

    • Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)

    • ALKS 2680 - Narcolepsy

  • Oncology

    • Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer

    • Nemvaleukin alfa - Mucosal Melanoma

*In combination with pembrolizumab
Neuroscience
Oncology
These programs are investigating treatments or outcomes that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. 






Last updated: February 2023

Careers

  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.blue triangle graphic


We are driven by some of the most pressing health issues of our time to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.